Call Now 201-447-2020   Toll Free 800-850-2101 |   Get Directions  |  Refills


T&C Compounding has the resources you need to conduct the most advanced research

Why Town & Country for your Clinical Research?

 Town & Country utilizes only:

  • State-of-the-art equipment
  • Highest quality ingredients
  • Innovative closing devices
  • Expert & highly trained sterile and non-sterile compounders

 Town & Country is committed to quality and patient safety

T&C is one of only 2% of compounding pharmacies nationwide who have achieved PCAB accreditation

  • PCAB accreditation is only achieved by pharmacies committed to compliance and continuous quality improvement
Town & Country can provide the necessary flexibility, variation, and customization by providing:
  • A range of medication strengths
  • Various dosage forms
  • Various routes of administration
  • Various excipients
  • Blinded or unblinded product
  • Smaller batch sizes
Compounding pharmacies are uniquely positioned to assist researchers by:
  • Reducing costs
  • Improving efficiency
  • Increasing Flexibility
  • Reducing production
 Pictured: Sterile Compounding for a Clinical Trial
at Town & Country Compounding Laboratory

 JOHN HERR, RPh, T&C Owner

With over 25 years of compounding experience, John Herr is considered to be one of the experts in the compounding industry.

  • Past President International Academy of Compounding Pharmacists (IACP)
  • PCCA Compounding Pharmacist of the Year, 2007
  • NJ Hospice Pharmacist of the year
  • Served on the following boards:
    • IACP, Board Member
    • CSPN, Board Member
    • MHA, Specialty Pharmacy Advisory Board
FDA Inspected and ACHC/PCAB Accredited Pharmacy.
New Jersey & NYC’s Expert Compounding Pharmacy.

 Phase I & II studies are often complex and expensive.

 Take advantage of T&C 503A Research Resources at a fraction of the cost of production compared to pharmaceutical manufacturers or 503B facilities.

Why use a 503A pharmacy?

Bring your product to market more quickly and less expensively.

  • Less testing required before product release which:
    • Reduces Laboratory testing cost
    • Reduces length of testing time
  • Allows the flexibility to prepare a number of different dosage, strengths, dosage forms, and routes of administration in response to emerging clinical data without multiplying the cost.
  • The amount of product prepared can be determined by the scope of the study.
503A vs. 503B Pharmacies

In the DOSA, the FDA distinguishes between 503A (compounding pharmacies) and 503B (pharmaceutical manufacturers) facilities.

Unlike 503B facilites,section 503A exempts compounding pharmacies from having to follow the FDA’s cGMP regulations as outlined in 21 CFR Part 211 and 21 CFR Part 210.

Instead, 503A pharmacies must follow the regulations set by the USP (United States Pharmacopeia ) Compounding Compendium and the NF (National Formulary)